Intuitive Surgical Company Profile (NASDAQ:ISRG)

Intuitive Surgical trades on the NASDAQ under the ticker symbol "ISRG."

Intuitive Surgical's stock split on the morning of Friday, October 6th 2017. The 3-1 split was announced on Friday, August 11th 2017. The newly issued shares were payable to shareholders after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Intuitive Surgical stock prior to the split would have 300 shares after the split.

Intuitive Surgical, Inc. (NASDAQ:ISRG) issued its earnings results on Thursday, October, 19th. The company reported $2.77 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.99 by $0.78. The firm had revenue of $806.10 million for the quarter, compared to analyst estimates of $753.25 million. Intuitive Surgical had a net margin of 30.16% and a return on equity of 18.34%. Intuitive Surgical's revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.06 earnings per share. View Intuitive Surgical's Earnings History.

16 brokers have issued twelve-month price targets for Intuitive Surgical's stock. Their predictions range from $75.00 to $353.33. On average, they expect Intuitive Surgical's stock price to reach $139.91 in the next year. View Analyst Ratings for Intuitive Surgical.

Here are some recent quotes from research analysts about Intuitive Surgical stock:

• 1. According to Zacks Investment Research, "Over the last three months, Intuitive Surgical was trading consistently ahead of the broader industry. While a stellar second-quarter 2017 result was a major market sentiment booster, the company gained significantly on the CE Mark approval for da Vinci X in Europe. The stock has got a further boost on the recent U.S. FDA approval of the same. A positive outlook for the coming quarters also raises our confidence in the stock. Further, incremental spending on product development and higher investments in international markets are prudent moves that are likely to drive long-term growth. The company is also expected to enhance its organizational capabilities and gain prominence in the markets of Europe and Asia. However, the da Vinci Surgical System has a long sale and purchase order cycle which might act against the company. In fact, the stock looks a tad expensive, adding to our concerns." (7/25/2017)
• 2. Cantor Fitzgerald analysts commented, "Procedure growth: Guidance for 2017 procedure growth appears to be conservative. ISRG had 17% procedure growth in the 1H and is guiding to 14-15% procedure growth for 2017, implying 11-13% procedure growth in the 2H. The first-half procedure growth came in above expectations, as gynecology (grew in low single digits) and urology (grew in mid-to-high single digits) and China (grew by well over 25%) outpaced expectations. Second-half guidance assumes slower growth in gynecology, urology, and China, one less selling day in 3Q, and lower growth in Japan due to a lack of reimbursement." (7/21/2017)
• 3. Canaccord Genuity analysts commented, "Our checks at the SAGES conference in Houston this week reaffirmed our near-term bullishness about the firm's fundamentals. A year ago coming out of this important trade show, we opined that a robotics revolution was underway in general surgery;our checks at SAGES 2017 suggest the revolution continues ' especially in hernia repair. Given the large opportunity open to robotic surgery ' nearly 1M annual hernia procedures in the U.S. of which nearly 70% are currently performed via an invasive, open surgery ' we discerned escalating enthusiasm from robotic surgeons. In sum, we think ISRG is positioned well to deliver procedure volume growth at or above its current guidance, which calls for 9-12% growth in 2017. On the competitive front, Medtronic looks to be at least a few years out, but seems to be ISRG's most imminent challenger. At an analyst meeting during SAGES yesterday, Medtronic updated its projections for entry into the surgical robotics arena, targeting initial market entry into a few small countries in Europe before the end of F2018 (April '18). Further, Medtronic expects FDA approval, as well as market expansion into larger European markets, during its F2019, with material revenue contributions expected over that timeframe. Meanwhile, we think ISRG (the company and the stock) still has room to run. We maintain our BUY rating and $800 price target." (3/24/2017)

Some companies that are related to Intuitive Surgical include Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Boston Scientific Corporation (BSX), Koninklijke Philips N.V. (PHG), Illumina (ILMN), Cerner Corporation (CERN), Edwards Lifesciences Corporation (EW), Agilent Technologies (A), Waters (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Quidel Corporation (QDEL) and Mazor Robotics (MZOR).

Intuitive Surgical's management team includes the folowing people:

• Lonnie M. Smith, Independent Chairman of the Board
• Gary S. Guthart Ph.D., President, Chief Executive Officer, Director
• Marshall L. Mohr, Chief Financial Officer, Senior Vice President
• Salvatore J. Brogna, Executive Vice President - Product Operations
• David J. Rosa, Executive Vice President, Chief Commercial Officer
• Mark J. Meltzer, Senior Vice President, Chief Compliance Officer, General Counsel
• Myriam J. Curet M.D., Senior Vice President, Chief Medical Officer
• Jamie E. Samath, Vice President, Corporate Controller, and Principal Accounting Officer
• Alan J. Levy Ph.D., Lead Independent Director
• Craig H. Barratt Ph.D., Independent Director

Intuitive Surgical's stock is owned by many different of institutional and retail investors. Top institutional shareholders include APG Asset Management N.V. (0.08%), Robeco Institutional Asset Management B.V. (0.04%), State Treasurer State of Michigan (0.01%), Wealth Enhancement Advisory Services LLC (0.01%), Shell Asset Management Co. (0.01%) and Bath Savings Trust Co (0.00%). Company insiders that own Intuitive Surgical stock include Alan J Levy, Amal M Johnson, Colin Morales, Curet Myriam, David J Rosa, Eric H Halvorson, Gary S Guthart, George Stalk Jr, Jamie Samath, Keith R Leonard, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Institutional Ownership Trends for Intuitive Surgical.

Intuitive Surgical's stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Shell Asset Management Co., State Treasurer State of Michigan and Bath Savings Trust Co. Company insiders that have sold Intuitive Surgical stock in the last year include Alan J Levy, Amal M Johnson, Colin Morales, Curet Myriam, David J Rosa, Gary S Guthart, Jamie Samath, Keith R Leonard, Lonnie M Smith, Mark J Meltzer, Mark J Rubash, Marshall Mohr, Michael A Friedman and Salvatore Brogna. View Insider Buying and Selling for Intuitive Surgical.

Intuitive Surgical's stock was bought by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Robeco Institutional Asset Management B.V., Wealth Enhancement Advisory Services LLC, Meeder Asset Management Inc. and Eqis Capital Management Inc.. View Insider Buying and Selling for Intuitive Surgical.

Shares of Intuitive Surgical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Intuitive Surgical stock can currently be purchased for approximately $369.58.